

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM321242

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
General Electric Capital Corporation, as Agent		10/24/2014	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Cytovance Biologics, Inc.		
<b>Street Address:</b>	800 Research Parkway, Suite 200		
<b>City:</b>	Oklahoma City		
<b>State/Country:</b>	OKLAHOMA		
<b>Postal Code:</b>	73104		
<b>Entity Type:</b>	CORPORATION: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2891313	CYTOVANCE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	3124996701		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	(312) 499-6700		
<b>Email:</b>	tapatterson@duanemorris.com		
<b>Correspondent Name:</b>	Brian P. Kerwin		
<b>Address Line 1:</b>	190 South LaSalle Street, Suite 3700		
<b>Address Line 2:</b>	Duane Morris LLP		
<b>Address Line 4:</b>	Chicago, ILLINOIS 60603		
<b>ATTORNEY DOCKET NUMBER:</b>	F6270-00010		
<b>NAME OF SUBMITTER:</b>	Brian P. Kerwin		
<b>SIGNATURE:</b>	/Brian P. Kerwin/		
<b>DATE SIGNED:</b>	10/27/2014		
<b>Total Attachments: 2</b>			
source=IP Release (GE)-Cytovance#page1.tif			
source=IP Release (GE)-Cytovance#page2.tif			

OP \$40.00 2891313

**RELEASE OF SECURITY INTEREST IN TRADEMARK**

THIS RELEASE is made as of this 24<sup>th</sup> day of October, 2014, by General Electric Capital Corporation, a Delaware corporation, as Agent ("Agent"), in favor of Cytovance Biologics, Inc., a Delaware corporation.

Agent, through a certain Trademark Security Agreement dated April 5, 2012, recorded in the United States Patent and Trademark Office on April 11, 2012, at Reel 004755, Frame 0286, established a lien and security interest to a trademark owned by Cytovance Biologics, Inc. attached hereto as Schedule A (the "Trademark"). The obligations of said Trademark Security Agreement have been fulfilled.

FOR GOOD AND VALUABLE CONSIDERATION, the receipt and adequacy of which are hereby acknowledged, Agent hereby unconditionally and expressly releases, terminates, and extinguishes any and all of its right, title and interest in and to any and all liens and security interests it may have upon the Trademark and any goodwill in favor of Cytovance Biologics, Inc.

This Release shall be binding upon Agent's legal representatives, assigns and successors.

**AGENT:**

General Electric Capital Corporation

By: 

Name: Peter Gibson

Title: Duly Authorized Signatory

**SCHEDULE A**

Country	Mark	Appl. No.	Appl. Date	Reg. No.	Reg. Date
United States	CYTOVANCE	78280279	6/29/2003	2891313	10/5/2004

KCP-4526527-1